Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Sikander Ailawadhi, Cooper Bussberg, Lei Chi, Phani Chintakayala, James Harnett, Timothy J Inocencio, Glenn S Kroog, Qiufei Ma, Carol Mansfield, Karen Rodriguez-Lorenc

Ngôn ngữ: eng

Ký hiệu phân loại: 353.73 *Public libraries

Thông tin xuất bản: England : Future oncology (London, England) , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 692142

AIMS: To quantify patient preferences for attributes of novel treatments for triple-class-exposed (TCE) relapsed and/or refractory multiple myeloma (RRMM). METHODS: Using a discrete-choice experiment, we elicited preferences for 7 attributes: objective response rate (ORR), overall survival (OS), all-grade cytokine release syndrome risk, all-grade immune effector cell-associated neurotoxicity syndrome risk, serious infection risk (grade 3+), treatment administration, and initial hospitalization requirements. RESULTS: OS was the most important attribute (conditional relative importance [CRI] 32.0% for a 24-month increase), followed by serious infection risk (CRI 17.3% for avoiding a 60% risk), initial hospitalization requirements (CRI 15.0% for avoiding 14 days of initial hospitalization), and ORR (CRI 13.7% for a 38% increase). Based on differences between relative preference weights, fewer initial hospitalization days when starting treatment and off-the-shelf (vs. chimeric antigen receptor T [CAR T] cell-like) options were significantly preferred. CONCLUSIONS: Therapy decisions for patients with TCE RRMM should consider tradeoffs between efficacy, safety, and attributes related to treatment process and initial monitoring.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH